Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02152462 · ClinicalTrials.gov registry record · Phase 2

Exergaming Intervention and Breast Cancer Biomarkers in Black Women

A Phase 2 study, sponsored by Georgetown University.

Completed
Registry status
Phase 2
Development phase
150
Enrollment target

NCT02152462: Completed Phase 2 study, sponsored by Georgetown University.

NCT02152462 is a Phase 2 study that has completed, run by Georgetown University. The registered enrollment target is 150 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (13% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02152462, a Phase 2 study, has completed, sponsored by Georgetown University.

COMPLETED
Registry status
Phase 2
Development phase
150 participants
Enrollment target

Study Summary

Overview: This is a 6 month, two-arm randomized clinical trial using comparing exergaming to a control group. The investigators will randomize Black sedentary overweight/obese women to Wii Fit exercise (n=50) or the control arm (n=50). Women in the Wii Fit exercise group will come to the Georgetown community-based exercise facility 3 days/wk. The control group will be asked to maintain their current daily activities and not to exercise for the duration of the study. Based on the investigators previous findings that women who engage in 75-150 mins/wk of brisk walking had an 18% decreased risk of breast cancer, the investigators will target this level of activity in the investigators intervention arm. Also, this 150 min/week of physical activity meets the current recommendations of the American College of Sports Medicine (ACSM) and the US Department of Health and Human Services for healthy individuals and is in line with recommendation of the American Cancer Society (ACS) for cancer prevention.

Primary Outcome

Outcomes for plasma leptin, adiponectin, Insulin-like growth factor 1 (IGF-1), Insulin-like growth factor-binding protein 3 (IGFBP3), C-reactive protein (CRP), Interleukin 6 (IL-6), insulin, c-peptide, and Hb-A1c levels at baseline and 24 weeks.

Interventions

  • OTHER Exergaming

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2012-12
Est. Completion 2019-12
Phase Phase 2
Georgetown University

227 total trials

What the finished NCT02152462 record still lists

NCT02152462 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (13% higher).

The record links to 0 conditions, and to 1 intervention - of which Exergaming is the first listed.

NCT02152462 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02152462 about?

NCT02152462 is a clinical study titled "Exergaming Intervention and Breast Cancer Biomarkers in Black Women". Overview: This is a 6 month, two-arm randomized clinical trial using comparing exergaming to a control group. The investigators will randomize Black sedentary overweight/obese women to Wii Fit exercise (n=50) or the control arm (n=50). Women in the Wii Fit exercise group will come to the Georgetown ...

What is the current status of trial NCT02152462?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2012-12. Estimated completion is 2019-12.

What interventions are being tested in trial NCT02152462?

The interventions under investigation include: Exergaming (OTHER).

Who is sponsoring clinical trial NCT02152462?

This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02152462's enrollment target sits among peer trials

150 455th of 2000 higher than 1,510 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00412594 · 150 participants · Phase 2

    Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

  • NCT01484730 · 150 participants

    A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion

  • NCT01985919 · 150 participants

    Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples

  • NCT02016248 · 150 participants · NA

    SBRT Boost for Unfavorable Prostate Cancer'

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02152462, the US trial registry maintained by the National Library of Medicine. NCT02152462 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.